Global, randomized Phase 2 study to evaluate the addition of givastomig, a CLDN18.2 x 4-1BB bispecific antibody (8 mg/kg and 12 mg/kg) to standard of care immunochemotherapy in patients with first lin ...
IDF soldier killed in so-called friendly fire incident in south Gaza * Leading religious Zionist rabbis tell PM to stop ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results